OneSource Specialty Pharma Ltd

AI
OneSource Speci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

OneSource Specialty Pharma Ltd

₹ 1,584 0.95%
04 Nov - close price
onesourcecdmo.com BSE: 544292 NSE: ONESOURCE
About

Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]

Key Points

Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.

Website BSE NSE
  • Market Cap ₹ 18,160 Cr.
  • Current Price ₹ 1,584
  • High / Low ₹ 1,918 / 1,057
  • Stock P/E 178
  • Book Value ₹ 531
  • Dividend Yield 0.00 %
  • ROCE 2.05 %
  • ROE 0.45 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 2.98 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Tax rate seems low
  • Company has a low return on equity of -1.16% over last 3 years.
  • Promoters have pledged 38.8% of their holding.
  • Company has high debtors of 191 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty 500 Multicap 50:25:25 BSE Healthcare BSE 500 Nifty Smallcap 100 BSE SmallCap Select Index

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
34 56 73 240 245 337 477 321 375 290 419 446 514
72 67 76 230 223 237 240 241 274 277 344 332 356
Operating Profit -38 -10 -3 10 22 99 237 80 102 13 75 114 158
OPM % -113% -18% -3.6% 4.3% 9% 30% 50% 25% 27% 4.4% 18% 26% 31%
-32 -74 3 -1 -3 -95 3 5 3 -2 4 4 1
Interest 25 26 20 41 44 44 32 27 33 38 22 31 34
Depreciation 18 20 20 34 33 34 34 33 34 35 35 36 39
Profit before tax -113 -130 -40 -65 -58 -73 174 25 37 -62 21 51 86
Tax % 0% 0% 0% -63% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-113 -130 -40 -24 -58 -73 174 25 37 -62 21 51 86
EPS in Rs -6.38 15.22 2.17 3.24 -5.43 1.87 4.47 7.52
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
21 132 39 172 1,300 1,405 1,670
93 228 156 254 930 1,136 1,310
Operating Profit -72 -96 -117 -82 370 269 360
OPM % -337% -72% -303% -48% 28% 19% 22%
1 4 -525 -143 -95 9 6
Interest 16 68 48 89 162 121 125
Depreciation 34 70 109 76 135 137 145
Profit before tax -121 -230 -799 -390 -22 21 97
Tax % 0% 0% 0% 0% -187% 0%
-121 -230 -799 -390 19 21 97
EPS in Rs 1.69 1.85 8.43
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 131%
3 Years: 231%
TTM: 11%
Compounded Profit Growth
10 Years: %
5 Years: 17%
3 Years: 27%
TTM: -61%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -14%
Return on Equity
10 Years: %
5 Years: -9%
3 Years: -1%
Last Year: 0%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 2 4 4 4 11 11 11
Reserves 777 1,012 783 394 5,909 5,939 6,077
386 1,154 864 571 942 1,504 1,755
98 275 363 457 635 916 885
Total Liabilities 1,262 2,445 2,014 1,426 7,497 8,370 8,728
633 1,231 1,361 863 3,200 3,198 3,631
CWIP 382 440 334 188 206 469 141
Investments 53 52 5 20 2,848 2,931 2,931
194 722 314 355 1,243 1,773 2,025
Total Assets 1,262 2,445 2,014 1,426 7,497 8,370 8,728

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-115 -420 -165 -109 -47 55
-210 -685 -66 506 -300 -478
381 1,159 118 -384 417 361
Net Cash Flow 56 55 -112 13 70 -61
Free Cash Flow -274 -1,069 -207 -173 -134 -421
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 159% 439% 150% 133% -11% 19%

Ratios

Standalone / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 38 101 35 118 124 191
Inventory Days 87 1,720 2,354 665 233 438
Days Payable 758 408 1,606 419 143 330
Cash Conversion Cycle -633 1,414 784 363 214 299
Working Capital Days -2,423 -1,288 -6,731 -873 -49 -18
ROCE % -10% -12% -12% 6% 2%

Insights

In beta
Dec 2023 Mar 2025 Mar 2026 Mar 2027 (P) Mar 2028 (P)
Cartridge Installed Capacity (DDC)
Million units per year

Log in to view insights

Please log in to see hidden values.

Login
Successful Regulatory and Customer Audits (Annual)
Count
Total Customers (Global)
Count
DDC Projects (Cumulative)
Count
Device Platforms (DDC)
Count
New MSAs / Licensing Agreements Signed (Annual)
Count
Soft Gelatin Capsule Installed Capacity
Billion units per year
Sterile Production Days Available (Annual)
Days per year

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
37.76% 34.25% 29.78% 29.77% 29.93% 30.48% 30.48% 30.47%
17.44% 18.54% 18.69% 19.39% 19.24% 17.50% 19.19% 19.45%
12.56% 18.03% 18.09% 18.48% 18.80% 20.61% 23.37% 24.20%
32.24% 29.17% 33.42% 32.34% 32.01% 31.40% 26.95% 25.86%
No. of Shareholders 98,42582,71287,76087,41684,59579,46077,89979,770

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls